re: isn't it time? - time for what ? Oh, being a long term...

re: isn't it time? - time for what ? Oh, being a long term investor vs being an impatient speculator can be so tricky.
Suggest it would be good to keep the interchange and expectations relevant.
Reading - no make that studying - the media releases from Ventracor should help put things into perspective.

Visit this site for latest information available to the public http://www.ventracor.com/

Start with this one and remember these things do not always stick to a fixed time plan:
=======================================
Company Announcement

Ventracor Artificial Heart Pilot Trial Update

VENTRACOR LIMITED 2003-04-23 ASX-SIGNAL-G

HOMEX - Brisbane
+++++++++++++++++++++++++
Ventracor Limited (ASX:VCR), today provided a progress repor t on the
Pilot Trial of the VentrAssist(TM)artificial heart at The Alfred
hospital in Melbourne.

The company said Pilot Tr ial preparations were on track and had
entered their final stages. Ventracor Managing Director and Chief
Executive Officer, Mr Michael Spooner, said that at a meeting with
the medical investigative team at The Alfred hospital yesterday,
Ventracor introduced an updated and improved ser ies of Data
Collection Forms. He said these forms would provide a basis for Pilot
Tr ial data to be collected as well as suppor ting the global Pivotal
Trial.

"This integrated approach may well provide Ventracor with significant
overall time savings in our race to obtain global regulatory approval
to sell the VentrAssist(TM) device.

"In effect, Ventracor is looking to incorporate Pilot Trial data into
our global Pivotal Tr ial submissions, a process that has only become
possible as a result of international developments in the past few
weeks.

"Ventracor key staff are working closely with the medical
investigative team at The Alfred hospital in Melbourne to facilitate
the implementation of the additional requirements in the new Data
Collection Forms.

"Ventracor is also assisting with the introduction of new clinical
tools which monitor patient condition and rehabilitation. These tools
will help in proving that the VentrAssist(TM) is the treatment of
choice for patients with severe heart failure.

"We are expecting the medical investigative team to finalise
recruitment of patients dur ing May with the first implant to be
performed in June.

"Ventracor will utilize this per iod of time to under take additional
rigorous testing of the final devices.

"We are delighted with the outcomes from our preclinical testing and
want to take every oppor tunity to ensure the success of the overall
trial process.

"Both Ventracor and The Alfred hospital are doing their utmost to
ensure patient wellbeing, dignity and privacy remain our primary
concern", Mr Spooner said.

For more information, please contact:

Michael Spooner Julie Meldrum
MANAGING DIRECTOR & CEO CORPORATE COMMUNICATIONS MANAGER
02 9406 3100 02 9406 3100 or 0419 228 128

.